Loading...
This has been an exciting year for us, with organizational changes that are reflected in our new title: NEJM Journal Watch AIDS Clinical Care. We remain devoted to providing clinicians with the information they need to give their patients the best care — and, as part of NEJM Group, we are now poised to do that better than ever.
The biggest change in HIV treatment over the past year has been the continued emergence of integrase inhibitor–based regimens as top options for first-line therapy. This trend began with raltegravir in the late 2000s, accelerated when co-formulated tenofovir/FTC/elvitegravir/cobicistat was approved in 2012, and now has been further strengthened by the recent approval of dolutegravir. In response to accumulating resear…